The Picower Institute for Medical Research

Cytokine Pharmasciences, Inc.

Jurgen Bernhagen

Anthony Cerami

Richard J Bucala

Robert A Mitchell

Thierry F Calandra

The present invention relates to compositions and methods for inhibiting the release and/or biological activity of migration inhibitory factor (MIF). In particular, the invention relates to the uses of such compositions and methods for the treatment of various conditions involving cytokine-mediated toxicity, which include, but are not limited to shock, inflammation, graft versus host disease, and/or autoimmune diseases.

Anti-MIF antibodies

A diagnostic method for determining MIF protein content in a sample using a direct or an indirect detection technique and wherein MIF is a human MIF protein having a molecular weight of approximately 12.5 kDa.

Method for determining MIF content

Composition containing anti-MIF antibody

Diagnostic assays for MIF

There is disclosed a method for treating an individual having a disease caused by cytokine-mediated toxicity comprising administering to the individual an effective amount of (a) an antibody that binds to an MIF polypeptide, wherein the MIF polypeptide has a molecular weight of about 12.5 kDa in combination with (b) anti-TNF.alpha., anti-IL1, anti-IFN-.gamma., IL-1RA, a steroid, a glucocorticoid, or IL-10.

Combination method for treating diseases caused by cytokine-mediated

Growing community of inventors

New York, NY, United States of America

Jurgen Bernhagen